PMID- 36705409
OWN - NLM
STAT- MEDLINE
DCOM- 20230201
LR  - 20230215
IS  - 2050-4527 (Electronic)
IS  - 2050-4527 (Linking)
VI  - 11
IP  - 1
DP  - 2023 Jan
TI  - Epitope identification for p53R273C mutant.
PG  - e752
LID - 10.1002/iid3.752 [doi]
LID - e752
AB  - BACKGROUND: With the rise of immunotherapy based on cancer neoantigen, 
      identification of neoepitopes has become an urgent problem to be solved. The TP53 
      R273C mutation is one of the hotspot mutations of TP53, however, the 
      immunogenicity of this mutation is not yet clear. The aim of this study is to 
      identify potential epitopes for p53R273C mutant. METHODS: In this study, 
      bioinformatic methods, peptide exchange assay, and peptide-immunized human 
      leukocyte antigen (HLA) transgenic mouse model were used to explore the 
      immunogenicity of this mutation. RESULTS: Peptides with higher affinity to common 
      HLA-A alleles (A*11:01, A*02:01) were discovered by computational prediction. All 
      the 8-11 mer peptides contain the mutation site were synthesized and soluble 
      peptides were used in the peptide exchange assay. However, the exchange 
      efficiencies of these predicted peptides to HLAs were lower. Fortunately, other 
      peptides with higher exchange efficiency were discovered. Then, the 
      immunogenicity of these peptides was validated with the HLA-A2 transgenic mice 
      model. CONCLUSION: We identified three potential neoepitopes of p53(R273C) for 
      HLA-A*02:01, one potential neoepitope for HLA-A*11:01 and no neoepitope for 
      HLA-A*24:02.
CI  - (c) 2022 The Authors. Immunity, Inflammation and Disease published by John Wiley & 
      Sons Ltd.
FAU - Zhang, Jian
AU  - Zhang J
AUID- ORCID: 0000-0001-8516-8651
AD  - School of Medicine, Nankai University, Tianjin, China.
AD  - Department of Oncology, Oncology Laboratory, Chinese PLA General Hospital, 
      Beijing, China.
AD  - Research and Development Department, Beijing DCTY Biotech Co., Ltd., Beijing, 
      People's Republic of China.
FAU - Liu, Minglu
AU  - Liu M
AD  - Department of Oncology, Oncology Laboratory, Chinese PLA General Hospital, 
      Beijing, China.
FAU - Chen, Yin
AU  - Chen Y
AD  - Research and Development Department, Beijing DCTY Biotech Co., Ltd., Beijing, 
      People's Republic of China.
FAU - Zhou, Zishan
AU  - Zhou Z
AD  - Research and Development Department, Beijing DCTY Biotech Co., Ltd., Beijing, 
      People's Republic of China.
FAU - Wang, Ping
AU  - Wang P
AD  - Research and Development Department, Beijing DCTY Biotech Co., Ltd., Beijing, 
      People's Republic of China.
FAU - Yu, Yang
AU  - Yu Y
AD  - Research and Development Department, Beijing DCTY Biotech Co., Ltd., Beijing, 
      People's Republic of China.
FAU - Jiao, Shunchang
AU  - Jiao S
AD  - School of Medicine, Nankai University, Tianjin, China.
AD  - Department of Oncology, Oncology Laboratory, Chinese PLA General Hospital, 
      Beijing, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Immun Inflamm Dis
JT  - Immunity, inflammation and disease
JID - 101635460
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Epitopes)
RN  - 0 (HLA Antigens)
RN  - 0 (Peptides)
RN  - 0 (Tumor Suppressor Protein p53)
SB  - IM
MH  - Animals
MH  - Humans
MH  - Mice
MH  - *Antigens, Neoplasm/genetics
MH  - Epitopes
MH  - HLA Antigens/genetics
MH  - Mice, Transgenic
MH  - *Neoplasms
MH  - Peptides/genetics
MH  - *Tumor Suppressor Protein p53/genetics
PMC - PMC9761341
OTO - NOTNLM
OT  - TP53 R273C mutation
OT  - immunogenicity
OT  - immunotherapy
OT  - neoantigen
COIS- Authors Yin Chen, Zishan Zhou Ping Wang, and Yu Yang are employed by Beijing DCTY 
      Biotech Co., Ltd., Beijing, China. The remaining authors declare that the 
      research was conducted in the absence of any commercial or financial 
      relationships that could be construed as a potential conflict of interest.
EDAT- 2023/01/28 06:00
MHDA- 2023/01/31 06:00
PMCR- 2022/12/19
CRDT- 2023/01/27 08:22
PHST- 2022/11/08 00:00 [revised]
PHST- 2022/09/06 00:00 [received]
PHST- 2022/12/02 00:00 [accepted]
PHST- 2023/01/27 08:22 [entrez]
PHST- 2023/01/28 06:00 [pubmed]
PHST- 2023/01/31 06:00 [medline]
PHST- 2022/12/19 00:00 [pmc-release]
AID - IID3752 [pii]
AID - 10.1002/iid3.752 [doi]
PST - ppublish
SO  - Immun Inflamm Dis. 2023 Jan;11(1):e752. doi: 10.1002/iid3.752.